During the study period, progress in cancer control (increased survival, decreased mortality and incidence) was seen for stomach, colon, lung (in men), and ovarian cancer.
There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.
Autologous activated killer T cells and dendritic cells from regional lymph nodes were infused with or without chemotherapy in the adjuvant setting.
IBM Watson Health’s Clinical Trials Matching (CTM) is an artificial intelligence system that can increase the efficiency of patient screening and recruitment into clinical trials.
There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.